We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+5.31%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$213M
AUM Growth
+$48.7M
Cap. Flow
+$48M
Cap. Flow %
22.55%
Top 10 Hldgs %
61.4%
Holding
41
New
3
Increased
28
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$5.07M
2
MRK icon
Merck
MRK
+$4.99M
3
ALKS icon
Alkermes
ALKS
+$4.47M
4
HRMY icon
Harmony Biosciences
HRMY
+$4.11M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$3.66M

Top Sells

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$2.96M
2
MOH icon
Molina Healthcare
MOH
+$2.82M
3
OPCH icon
Option Care Health
OPCH
+$1.51M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$688K
5
MGNX icon
MacroGenics
MGNX
+$609K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.06T
$27.1M 12.73%
30,564
+3,420
+13% +$3.07M
UNH icon
2
UnitedHealth
UNH
$367B
$20.8M 9.75%
35,490
+3,810
+12% +$2.15M
MRK icon
3
Merck
MRK
$317B
$17.6M 8.26%
154,699
+41,965
+37% +$4.99M
TMO icon
4
Thermo Fisher Scientific
TMO
$214B
$13.6M 6.4%
22,012
+2,554
+13% +$1.51M
AMGN icon
5
Amgen
AMGN
$219B
$9.33M 4.39%
28,965
+1,376
+5% +$450K
BSX icon
6
Boston Scientific
BSX
$71.4B
$8.9M 4.18%
106,172
-385
-0.4% -$30.3K
ABBV icon
7
AbbVie
ABBV
$431B
$8.79M 4.13%
44,486
+8,868
+25% +$1.66M
SYK icon
8
Stryker
SYK
$129B
$8.48M 3.98%
23,460
+3,477
+17% +$1.2M
COR icon
9
Cencora
COR
$63.2B
$8.23M 3.87%
36,544
+6,224
+21% +$1.44M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$123B
$7.9M 3.71%
16,993
+1,898
+13% +$912K
REGN icon
11
Regeneron Pharmaceuticals
REGN
$79.5B
$7.39M 3.47%
7,028
+135
+2% +$150K
NBIX icon
12
Neurocrine Biosciences
NBIX
$16.2B
$6.98M 3.28%
60,607
+36,977
+156% +$5.07M
ALKS icon
13
Alkermes
ALKS
$8.11B
$6.62M 3.11%
236,610
+167,810
+244% +$4.47M
ITCI
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.19M 2.91%
84,578
+48,737
+136% +$3.66M
HRMY icon
15
Harmony Biosciences
HRMY
$2.26B
$6.08M 2.86%
151,875
+116,975
+335% +$4.11M
UFPT icon
16
UFP Technologies
UFPT
$2.41B
$5.72M 2.69%
18,048
+8,248
+84% +$2.63M
MIRM icon
17
Mirum Pharmaceuticals
MIRM
$5.74B
$5.39M 2.54%
138,321
+63,121
+84% +$2.52M
DXCM icon
18
DexCom
DXCM
$31.3B
$3.6M 1.69%
53,757
+19,274
+56% +$1.58M
ACLX
19
DELISTED
Arcellx
ACLX
$3.36M 1.58%
40,230
+17,734
+79% +$1.18M
IONS icon
20
Ionis Pharmaceuticals
IONS
$9.06B
$3.31M 1.56%
82,691
+42,000
+103% +$1.95M
CAH icon
21
Cardinal Health
CAH
$55.7B
$3.04M 1.43%
27,500
– –
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$2.94M 1.38%
275,472
+127,265
+86% +$1.39M
MRUS
23
DELISTED
Merus
MRUS
$2.53M 1.19%
50,687
+19,850
+64% +$1.04M
EW icon
24
Edwards Lifesciences
EW
$51.5B
$2.41M 1.13%
36,505
– –
NAMS icon
25
NewAmsterdam Pharma
NAMS
$3.23B
$2.31M 1.08%
138,983
+63,189
+83% +$1.09M
1
2

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return

HealthInvest Partners's Q3 2024 Portfolio in Review

As of Q3 2024, HealthInvest Partners held 41 positions worth $213M, up 30% from $164M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

HealthInvest Partners deployed $48M of net new capital in Q3 2024, opening 3 new positions and adding to 28 existing holdings. Its largest new stake was Soleno Therapeutics: 26,390 shares worth $1.33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Boston Scientific, an estimated $30.3K trimmed.

  • HealthInvest Partners's largest Q3 2024 buy was Soleno Therapeutics: 26,390 shares worth $1.33M.
  • HealthInvest Partners added most to Neurocrine Biosciences in Q3 2024, an estimated $5.07M increase.
  • HealthInvest Partners's biggest Q3 2024 reduction was Boston Scientific, cutting an estimated $30.3K.
  • HealthInvest Partners fully exited IQVIA in Q3 2024, selling an estimated $2.96M.
  • HealthInvest Partners's ten largest holdings make up 61% of its $213M portfolio in Q3 2024.
  • HealthInvest Partners opened 3 new positions and closed 5 in Q3 2024.
  • HealthInvest Partners's portfolio value rose 30% quarter-over-quarter to $213M.

Based on HealthInvest Partners's 13F filing for Q3 2024, filed 12 Nov 2024.